3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
2
Suspended
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Interventions
pembrolizumab
66
Cyclophosphamide
44
Cisplatin
43
Nivolumab
36
Paclitaxel
32
Carboplatin
31
Radiotherapy
29
Gemcitabine
28
Docetaxel
25
Dexamethasone
22
atezolizumab
21
Doxorubicin
19
Bevacizumab
19
Magnetic Resonance Spectroscopy
17
fludarabine
16
Vincristine
16
Lenalidomide
16
Etoposide
16
Radiosurgery
15
Letrozole
15
Ipilimumab
15
Fluorouracil
15
Blood Specimen Collection
15
palbociclib
14
Rituximab
14
Radiation
14
Leucovorin
14
Cytarabine
14
Surveys and Questionnaires
13
Specimen Handling
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Glucose
×
90 days
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts